BioSpace News Archive

Seegene (KQ096530), a biotechnology company specializing in molecular diagnostics, said Monday it finished the development of the world’s first-ever variant diagnostic test that can simultaneously detect COVID-19 and screen multiple virus variants, with a single multiplex real-time PCR testing

Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the pricing of an upsized underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $70.00 per share.

Ibere Pharmaceuticals (the “Company”) announced today that it closed its initial public offering of 13,800,000 units at $10.00 per unit, which included the exercise in full of the underwriter’s over-allotment option to purchase 1,800,000 Units.

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty products, announced the pricing of an underwritten public offering of 940,860 shares of its common stock at a price to the public of $186.00 per share, for gross proceeds of approximately $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Heska.

Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will participate in the Loop Capital Markets 2nd Annual Consumer, Industrial, and TMT Conference, taking place virtually on March 11th and 12th, 2021.

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA.

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced that Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Radioisotopes, will present at the H.C. Wainwright Global Life Sciences Conference,

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a partnership with leading health system Providence to advance the science and delivery of cancer care

Fifth EyeTM, a provider of intuitive real-time clinical analytics, today announced the U.S. Food and Drug Administration (FDA) has granted De Novo classification for its Analytic for Hemodynamic Instability (AHI).

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.